Table 4.

The influence of chronic treatment with 1MeTIQ and 1BnTIQ on the concentration of aspartate (ASP) and glutamate (GLU) in rat front al cortex

Treatment	N	ASP (ng/20 µl)	GLU (ng/20 µl)
Frontal cortex
Saline	5	464 ± 15	1998 ± 53
1BnTIQ/25 × 1	7	447 ± 17	2005 ± 42
1BnTIQ/25 × 14	6	588 ± 42**	2273 ± 161*
1MeTIQ/25 × 14	5	498 ± 10	2133 ± 100
1MeTIQ/50 × 14	6	520 ± 21	1988 ± 38
1MeTIQ/25 × 14 + 1BnTIQ/25 × 14	6	477 ± 16++	1998 ± 55+
1MeTIQ/50 × 14 + 1BnTIQ/25 × 14	6	530 ± 15	2067 ± 45
F		F (6/35) = 4.77 P < 0.01	F (6/35) = 1.65  N.S.

1BnTIQ (25 mg/kg i.p.) was administered acute or chronically during 14 consecutive days. 1MeTIQ was given in two doses (25 and 50 mg/kg i.p.) chronically. In the mixed group, 1MeTIQ was given also chronically, 20 min before each 1BnTIQ administration. Rats were decapitated 2 h after the injections. The results are expressed as the means ± SEM of five to seven samples (n = 5–7 animals per group). Data were analyzed with a one-way ANOVA followed by Duncan’s post hoc test. Statistical significance: * P < 0.05; ** P < 0.01 versus saline group; ⁺ P < 0.05; ⁺⁺ P < 0.01 versus 1BnTIQ group